TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3333162
Drug: Pentoxifylline (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (1200 mg/day per os, Trental 400 t.i.d.)
Study: 25002731
Drug: Methylprednisolone (MP)
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone (MP) 16 mg twice daily
Study: 16358378
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UH)
Study: 1835229
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B immunoglobulin (HBIg) and recombinant hepatitis B vaccine (HBvaxDNA) with an intensive schedule (0, 1 months for HBIg; 0, 1, 2, 6 months for vaccine)
Study: 1835229
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B immunoglobulin (HBIg) and recombinant hepatitis B vaccine (HBvaxDNA) for males
Study: 6188917
Drug: pindolol (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: pindolol (average 12 mg/day)
Study: 11901445
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 3200 microg of budesonide
Study: 9740606
Drug: Lisinopril (n=84)
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril (n=84)
Study: 9740606
Drug: Lisinopril plus
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril plus hydrochlorothiazide (n=91)
Study: 9740606
Drug: Lisinopril and
Normalized name: lisinopril and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril and Lisinopril plus hydrochlorothiazide
Study: 2112166
Drug: 2% mupirocin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% mupirocin ointment (Bactroban)
Study: 7044804
Drug: Fenbufen (600-1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenbufen (600-1000 mg/day, b.i.d.)
Study: 7044804
Drug: Indomethacin (750-125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (750-125 mg/day, b.i.d.)
Study: 30705040
Drug: Intravitreal ziv-aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ziv-aflibercept (IVZ) 1.25 mg/0.05 mL administered 1-10 days before PPV
Study: 30705040
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab (IVB) 1.25 mg/0.05 mL administered 1-10 days before PPV
Study: 29246725
Drug: Curcumin (Theracurmin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (Theracurmin® 90 mg twice daily)
Study: 26707868
Drug: OP (FemSeven
Approvals — FDA: no, EMA: no, PMDA: no
Description: OP (FemSeven 100μg/24h patches)
Study: 22715739
Drug: Dahuang Zhechong
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dahuang Zhechong Wan combined with adefovir dipivoxil (10 mg of adefovir dipivoxil once a day, 1 Wan each time, combined with Dahuang Zhechong Wan, 3 times a day, 1 Wan each time)
Study: 6332895
Drug: Soy isolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isolate formula supplemented with calcium (92 mg/kg/day), phosphorus (44 mg/kg/day), and vitamin D (500 IU/kg/day)
Study: 21865946
Drug: Neoadjuvant chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemoradiation therapy (CRT)
Study: 20569667
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of complementary and alternative medicine (CAM)
Study: 10476746
Drug: Imipenem (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem (50 mg/(kg x d))
Study: 10476746
Drug: Ceftazidime (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (120 mg/(kg x d))
Study: 9004051
Drug: Fluvoxamine (50-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (50-150 mg/day)
Study: 8899132
Drug: Fluvoxamine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (50 mg/day)
Study: 31819319
Drug: GLP‐1 infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP‐1 infusion (1.5 pmol/kg/min)
Study: 31819319
Drug: Placebo (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (500 mL of 0.9% saline)
Study: 27839782
Drug: 0.5mg/kg ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5mg/kg ketamine infusion
Study: 16828804
Drug: Rasagiline 1
Normalized name: rasagiline 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasagiline 1 mg
Study: 21482191
Drug: Rasagiline 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasagiline 2 mg
Study: 17915406
Drug: Transdermal regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal regimen
Study: 15043514
Drug: Aloe vera
Normalized name: ALOE VERA
DrugBank: Aloe vera leaf (DB13906)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aloe vera gel (100 mL twice daily for 4 weeks)
Study: 9110921
Drug: Low-dose beta-hCG
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose beta-hCG (2500-25000 IU/day)
Study: 9110921
Drug: High-dose beta-hCG
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose beta-hCG (25000-100000 IU/day)
Study: 9110921
Drug: Beta-hCG therapy
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-hCG therapy
Study: 8478852
Drug: Pulsed electromagnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed electromagnetic fields (PEMF) treatment for osteoarthritis; 18 half-hour periods of exposure over about 1 month.
Study: 30678686
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) with combination nutraceutical treatment (CT) 2000 mg/day
Study: 19414635
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human a-galactosidase A treatment for 5 months
Study: 19414635
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for 5 months
Study: 15386481
Drug: Almotriptan 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almotriptan 200 mg
Study: 15386481
Drug: Almotriptan 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almotriptan 150 mg
Study: 15386481
Drug: Almotriptan (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almotriptan (various doses 5-200 mg)
Study: 10092916
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen (HBO) treatment: Daily 100-minute treatments with 100% oxygen at 2.8 atmospheres absolute for three days (or six days for clinically abnormal patients).
Study: 10092916
Drug: Normobaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normobaric oxygen (NBO) treatment: Daily 100-minute treatments with 100% oxygen at 1.0 atmosphere absolute for three days (or six days for clinically abnormal patients).
Study: 7759785
Drug: Progesterone i.m.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone i.m. (50 mg/day)
Study: 7759785
Drug: Progesterone vaginal
Normalized name: progesterone Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone vaginal cream (100 mg/day)
Study: 44124
Drug: Lormetazepam 0.0635
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lormetazepam 0.0635 to 0.5 mg/70 kg
Study: 44124
Drug: Lormetazepam 1
Normalized name: lormetazepam 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lormetazepam 1 mg/70 kg
Study: 44124
Drug: Lormetazepam 2‐4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lormetazepam 2‐4 mg/70 kg
Study: 21910341
Drug: Astragalus treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astragalus treatment (Group A)
Study: 21910341
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of astragalus and hormone (Group C)
Study: 16986348
Drug: Bisphosphonates (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisphosphonates (oral and intravenous) such as alendronate, risedronate, ibandronate, pamidronate, and zoledronic acid
Study: 7756047
Drug: Bisphosphonate therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisphosphonate therapy
Study: 8776154
Drug: Needle-free injection
Normalized name: Stratis Needle-Free Injection Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needle-free injection with the Biojector
Study: 8776154
Drug: Needle and
Normalized name: syringe with needle and cannula, disposable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needle and syringe injections
Study: 6130246
Drug: Sodium stibogluconate
Normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium stibogluconate 20 mg/kg body weight (higher dose)
Study: 6130246
Drug: Sodium stibogluconate
Normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium stibogluconate 10 mg/kg body weight (lower dose)
Study: 3525023
Drug: PY 108-068
Normalized name: KETOCONAZ 2% GEL/ZINC PY 1% SHAMPOO KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: PY 108-068 (150 mg)
Study: 9184390
Drug: Aspirin 300
Normalized name: aspirin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 300 mg/day
Study: 16393327
Drug: Matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo (twice daily into each nostril for 7 days)
Study: 6434911
Drug: nasoenteric solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: nasoenteric solutions
Study: 29587861
Drug: CoQ10 pre-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoQ10 pre-treatment for 60 days preceding IVF-ICSI cycle
Study: 27206690
Drug: Low-dose group
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose group (3 to 7 spheroids/cm²)
Study: 27206690
Drug: Medium-dose group
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose group (10 to 30 spheroids/cm²)
Study: 27206690
Drug: High-dose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose group (40 to 70 spheroids/cm²)
Study: 24981149
Drug: Transdermal gel-based
Normalized name: BAKING POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal gel-based male hormonal contraceptive regimen (testosterone and Nestorone® gels)
Study: 20447094
Drug: 500-mL water
Normalized name: water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500-mL water drinking test (WDT)
Study: 20447094
Drug: 1000-mL water
Normalized name: water 1000 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000-mL water drinking test (WDT)
Study: 2977393
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg amlodipine
Study: 1737545
Drug: Topical 0.075%
Normalized name: capsaicin topical 0.075% topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.075% capsaicin applied 4 times/day
Study: 1737545
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream applied 4 times/day
Study: 30725092
Drug: Extended-release naltrexone
Normalized name: bupropion / naltrexone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release naltrexone
Study: 26875224
Drug: Misoprostol (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (600 μg oral)
Study: 12495134
Drug: New measures
Approvals — FDA: no, EMA: no, PMDA: no
Description: New measures of the proportion of treatment effect explained by a surrogate marker
Study: 10088944
Drug: Flow cytometry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flow cytometry using monoclonal antibodies (HLA‐ABC‐m3, GS145.2, FD705)
Study: 10088944
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of flow cytometry and DNA typing
Study: 6361099
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy (control group)
Study: 2349956
Drug: Short-term r‐HuEPO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-term r‐HuEPO therapy (n = 4)
Study: 2349956
Drug: Long-term r‐HuEPO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-term r‐HuEPO therapy (n = 8)
Study: 2349956
Drug: Placebo therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo therapy (n = 4)
Study: 2349956
Drug: r‐HuEPO therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: r‐HuEPO therapy (n = 8)
Study: 14528103
Drug: 1 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/kg body weight IVIG per day for 2 consecutive days (total dose 2 g/kg)
Study: 14528103
Drug: 0.3 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 g/kg body weight IVIG per day for 2 consecutive days (total dose 0.6 g/kg)
Study: 10863894
Drug: Serum free
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum free IGF-I levels in children with complete growth hormone deficiencies (cGHD)
Study: 10863894
Drug: Serum free
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum free IGF-I levels in children with partial growth hormone deficiencies (pGHD)
Study: 17179251
Drug: Gabapentin 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 1.2 g p.o. before surgery
Study: 17179251
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules 1 h before surgery
Study: 8940976
Drug: Ivermectin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (200 micrograms/kg single dose)
Study: 8940976
Drug: Albendazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (400 mg/day for three days)
Study: 30811371
Drug: Nicotine Patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine Patch (NRT)
Study: 29215395
Drug: Topical tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tacrolimus 0.05% as adjuvant therapy to corticosteroids
Study: 29215395
Drug: Corticosteroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid treatment only
Study: 10321141
Drug: Adjunctive orthognathic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive orthognathic surgery
Study: 12470183
Drug: Rasagiline 1
Normalized name: rasagiline 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasagiline 1 mg per day
Study: 23735181
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 200 μg (FP) alone
Study: 17976289
Drug: Problem-solving treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-solving treatment for a sub-group of patients with more severe pathology.
Study: 7943220
Drug: Low-dose insulin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose insulin infusion (132 +/‐ 6 pM)
Study: 3349551
Drug: Epidural anaesthesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural anaesthesia combined with light general anaesthesia and postoperative pain relief with intermittent doses of bupivacaine
Study: 3349551
Drug: General anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anaesthesia with non-narcotic analgesics
Study: 25823958
Drug: Secukinumab 10
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Secukinumab 10 mg/kg IV (baseline, weeks 2 and 4)
Study: 25823958
Drug: Secukinumab 300
Normalized name: secukinumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 300 mg SC (baseline, week 4)
Study: 25823958
Drug: Secukinumab 10
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Secukinumab 10 mg/kg IV
Study: 24351993
Drug: Fall prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fall prevention program (laughter therapy, exercise, foot care, education), provided once a week for 8 weeks, each session lasting 80 minutes
Study: 24351993
Drug: Fall prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fall prevention program (laughter therapy, exercise, foot care, education)
Study: 8984034
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of solutions containing 12 to 36% of calories as protein, 24 to 48% as fat, and 40 to 64% as carbohydrate at 40, 90, or 160 kcal/h for 300 minutes.
Study: 8984034
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of sodium chloride (9 g/l) added to 16 infusates; osmolality of other 10 infusates was 24 to 98 mOsm.
Study: 8984034
Drug: Infusions at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusions at 40 and 90 kcal/h.
Study: 2052894
Drug: 0.05% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% chlorhexidine gluconate and 0.04% NaF rinsing solution (CXF)
Study: 30841655
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of policosanol
Study: 30841655
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of policosanol
Study: 21959320
Drug: Clopidogrel therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel therapy
Study: 12062320
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg im T enanthate weekly for 8 weeks (eugonadal group)
Study: 12062320
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg im sodium chloride weekly for 8 weeks (eugonadal control group)
Study: 12062320
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg im T enanthate biweekly for 8 weeks (hypogonadal group)
Study: 17146383
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g intravenous acetaminophen (Perfalgan)
Study: 12681003
Drug: Topiramate (TPM)
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (TPM) 50 mg/day
Study: 15624081
Drug: Topiramate (TPM)
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (TPM) 100 mg/day
Study: 12681003
Drug: Topiramate (TPM)
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (TPM) 200 mg/day (nonobese)
Study: 12681003
Drug: Topiramate (TPM)
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (TPM) 200 mg/day (obese)
Study: 15955935
Drug: Carbamazepine (CBZ)
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine (CBZ) 600 mg/day
Study: 10741623
Drug: Diltiazem 60
Normalized name: DILTIAZEM 60MG 12HR CAP,SA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 60 mg three times a day
Study: 10741623
Drug: Mibefradil 50
Normalized name: mibefradil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mibefradil 50 mg once a day
Study: 29656304
Drug: Gentamicin-collagen implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin-collagen implant (GCI) applied in the pelvic cavity after total mesorectal excision (TME)
Study: 29656304
Drug: Gentamicin-collagen implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin-collagen implant (GCI)
Study: 19776646
Drug: Repeat beta-methasone
Normalized name: beta-Methasone alcohol
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Repeat beta-methasone (12 mg)
Study: 15362516
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg TU plus 300 mg DMPA (Group C)
Study: 7954484
Drug: Moclobemide (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (300 mg daily)
Study: 12932798
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg daily)
Study: 29777264
Drug: Empagliflozin 10
Normalized name: empagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 10 mg or 25 mg once daily
Study: 22541842
Drug: Newly developed
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newly developed mirtazapine tablet formulation
Study: 22541842
Drug: Established branded
Normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Established branded mirtazapine tablet formulation
Study: 10795771
Drug: Octreotide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (100 microg bolus intravenous, followed after 2 h by a continuous infusion of 25 microg/hr for 20 hr)
Study: 10342414
Drug: Vehicle (placebo)
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (placebo) patch
Study: 2149674
Drug: 5, 10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5, 10, 20, or 40 mg of fosinopril orally once daily for four weeks
Study: 2149674
Drug: Matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo orally once daily for four weeks
Study: 7025264
Drug: Tri-potassium di-citrato
Normalized name: di-isopropylammonium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tri-potassium di-citrato bismuthate (TDB) chewing tablets
Study: 6397848
Drug: Cimetidine tablets
Normalized name: Cimetidine Tablets
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine tablets
Study: 22027686
Drug: Low-fat diet
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat diet with 5 grams of fish oil daily (omega-6:omega-3 ratio of 2:1)
Study: 15387158
Drug: Improved treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Improved treatment adherence
Study: 6241767
Drug: 10 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 micrograms HBV vaccine
Study: 6241767
Drug: 20 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 micrograms HBV vaccine
Study: 6241767
Drug: 40 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 micrograms HBV vaccine
Study: 23796764
Drug: Baerveldt implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baerveldt implant
Study: 29526236
Drug: Amla (Phyllanthus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amla (Phyllanthus emblica L.) 500 mg tablets, two tablets twice a day for 4 weeks